340B Drug Pricing Program
The U.S. Court of Appeals for the 5th Circuit today affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin enforcement of the state’s law protecting 340B pricing for contract pharmacy arrangements.
Several states have enacted laws protecting 340B contract pharmacy arrangements by requiring drug manufacturers to honor discounted pricing at those locations to preserve patient access. Manufacturers have challenged these laws in courts nationwide. This webpage compiles decisions in those cases as…
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted how certain 340B hospitals could make initial drug purchases.
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia blocking the state from enforcing S.B. 325, its law requiring drug companies to provide access to 340B drug discounts to purchases through…
Submit letters on 340b rebate model by April 20.
AHA President and CEO Rick Pollack testimony before the House Committee on Energy and Commerce Subcommittee on Health on Lowering Health Care Costs for All Americans: An Examination of the U.S. Provider Landscape.
Urge your Representative to sign Hill Letter on 340B Rebate Model.
The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect by April 1.
The AHA today urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect by April 1.
AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.